Current findings for Able
We could not establish a current primary-source identity for this provider from the research below. Earlier prices, service ratings, medication claims, and fictional experiences have been withdrawn. This is an evidence limitation, not a finding of misconduct. Do not treat this page as confirmation that treatment is available.
Identity needs confirmation
The older page linked to able.com and described a specific compounded-medication program. Our broader and exact-name Tinyfish searches did not establish a matching current primary provider page. Do not assume another service using the word Able is the same business.
Understand the medication before comparing providers
Approved weight-management options include Wegovy (semaglutide), Zepbound (tirzepatide) and Foundayo (orforglipron), each with its own indication, formulation and instructions. Ozempic and Mounjaro are diabetes brands. The current provider findings above identify what could be verified about this company; this general comparison does not establish that it offers every named medicine.
Wegovy has injectable and oral formulations, Zepbound is injectable, and Foundayo is oral. A compounded or dissolvable product is not the approved branded product. Identify the exact prescription and route before comparing price or applying a trial result.
Sources: Wegovy prescribing information · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information · Foundayo prescribing information
Compounded medicines are not FDA-approved. FDA recommends them only when a patient’s medical needs cannot be met by an approved medicine. Its April 2026 update says semaglutide and tirzepatide are not on the drug shortage list or the 503B bulks list. Patient-specific exceptions and other legal conditions matter; a “personalized” label, vitamin additive, or pharmacy registration does not by itself establish compliance or effectiveness.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA · FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
Safety questions for the prescribing clinician
The approved products cited here have a boxed warning about thyroid C-cell tumors in rodents; whether they cause these tumors in humans is unknown. Their contraindications include a personal or family history of medullary thyroid carcinoma (MTC), MEN 2, and specified serious allergic reactions. These are specific conditions, rather than a statement that every thyroid disorder rules out treatment. Review the exact product label with your clinician.
Tell the clinician about severe stomach-emptying problems, pancreatitis or gallbladder history, kidney concerns, diabetic eye disease, and every medicine or supplement you use. The labels do not recommend these products in severe gastroparesis. Insulin and medicines such as sulfonylureas can increase low-blood-sugar risk when used with them; adjustments belong with the prescriber. These examples do not replace the full safety review.
For weight management, Wegovy should be discontinued when pregnancy is recognized, and its label calls for stopping at least two months before a planned pregnancy. Ozempic also specifies at least two months before a planned pregnancy. Discuss the plan before trying to conceive. Wegovy tablets are not recommended during breastfeeding; the injection requires its own benefit-and-risk discussion.
Zepbound should be discontinued when pregnancy is recognized. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives: the Zepbound and Mounjaro labels advise a non-oral method or an added barrier method for four weeks after starting and for four weeks after each dose increase. Ask the clinician about pregnancy planning and breastfeeding for the exact prescription.
Foundayo also calls for discontinuation when pregnancy is recognized. Its oral-contraceptive precautions use 30 days after starting and 30 days after each dose increase. It is not recommended for nursing women. Do not substitute one product’s contraception or pregnancy instructions for another’s.
Sources: Wegovy prescribing information · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information · Foundayo prescribing information
Severe abdominal pain that does not go away, with or without vomiting, can be a pancreatitis warning; the labels instruct patients to stop the medicine and seek medical help promptly. Repeated vomiting or inability to keep fluids down also needs prompt assessment. For trouble breathing or swallowing, swelling of the face, tongue or throat, or collapse suggesting a serious allergic reaction, call 911 or your local emergency number immediately. Your provider should explain urgent and after-hours care before treatment starts.
Sources: Wegovy prescribing information · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information · Foundayo prescribing information · Anaphylaxis: MedlinePlus Medical Encyclopedia
Tell the anesthesia or procedure team about treatment before surgery or deep sedation. Do not independently combine GLP-1 products, shorten injection intervals or restart an old high dose after a break. Procedure planning and side effects and warning symptoms explain the questions to resolve with the care team.
Sources: Wegovy prescribing information · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information · Foundayo prescribing information
Questions to resolve before paying Able
- Which exact medication and formulation would my prescription specify, and which pharmacy would dispense it?
- What are the total first and renewal payments, and does the advertised monthly price require prepayment?
- Who manages side effects and dose changes, and what follow-up care is included?
- What is the cancellation deadline, and which fees remain non-refundable?
Ask for a written quote showing the medication, care or membership fee, labs, shipping, supplies, first payment, renewal payment, and cancellation cutoff. A monthly equivalent on a prepaid plan is different from paying that amount every month. A four-week supply and a calendar-month subscription also have different annual totals.
Verify your prescriber’s license and the dispensing pharmacy with the relevant state boards. Check that the pharmacy named on your prescription matches the pharmacy on the package. If injectable medication arrives warm or inadequately refrigerated, FDA advises against using it; contact the dispensing pharmacy for instructions. Avoid products sold as research chemicals or without a prescription.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
How to use this profile
This is a review of public information, not a hands-on clinical test or a verified patient review. We do not assign star ratings to clinical care, medication quality, response time, or shipping. An advertised benefit remains a provider claim unless independent evidence supports the specific claim. Confirm current availability, state eligibility, and the final terms directly before enrolling.
Read our source and correction policy and commercial disclosure. Medical review has not been completed.